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ABSTRACT 
 
Peroxisome proliferator–activated receptor-γ coactivator (PGC)-1α has been shown to 
play critical roles in regulating mitochondrial biogenesis, respiration, and muscle oxidative 
phenotype. Furthermore reductions in the expression of PGC-1α in muscle have been implicated 
in the pathogenesis of type 2 diabetes. To determine the effect of increased muscle specific PGC-
1α expression on muscle mitochondrial function and glucose and lipid metabolism in vivo, we 
examined body composition, energy balance, liver and muscle insulin sensitivity by 
hyperinsulinemic-euglycemic clamp studies, and muscle energetics using 31P Magnetic 
Resonance Spectroscopy in transgenic mice. Increased expression of PGC-1α in muscle resulted 
in a 2.4 fold increase in mitochondrial density, which was associated with an ~60% increase in 
the unidirectional rate of ATP synthesis. Surprisingly, there was no effect of increased muscle 
PGC-1α expression on whole body energy expenditure and PGC-1α TG mice were more prone 
to fat-induced insulin resistance due to decreased insulin-stimulated muscle glucose uptake. The 
reduced insulin-stimulated muscle glucose uptake could most likely be attributed to a relative 
increase in fatty acid delivery/triglyceride reesterfication, as reflected by increased expression of 
CD36, DGAT1 and mtGPAT, that may have exceeded mitochondrial fatty acid oxidation 
resulting in increased intracellular lipid accumulation and an increase in the membrane to cytosol 
diacylglycerol content. This in turn caused activation of PKCθ, decreased insulin signalling at 
the level of IRS-1 tyrosine phosphorylation and skeletal muscle insulin resistance. 
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Introduction 
Type 2 diabetes is the most common metabolic disease in the world and although the 
primary cause of this disease is unknown, it is clear that insulin resistance plays an early and 
critical role in its pathogenesis (1-3). Many studies suggest that net lipid accumulation (4-6), due 
to an imbalance between fatty acid delivery/synthesis and fatty acid oxidation, results in 
activation of a serine kinase cascade. This in turn inhibits insulin signalling resulting in insulin 
resistance in liver and skeletal muscle, the organs responsible for the majority of glucose 
disposal. Studies in transgenic and knockout mice have demonstrated that alterations in fatty acid 
delivery (5, 7), synthesis (8) or mitochondrial (9-11)/peroxisomal (12) fatty acid oxidation can 
alter this balance resulting in insulin resistance when there is a net increase in intracellular 
diacylglycerol content and protection from insulin resistance when there is a net reduction in 
intracellular diacylglycerol content. 
Peroxisome proliferator–activated receptor-γ coactivator (PGC-1α) is a critical regulator 
of mitochondrial biogenesis in skeletal muscle and promotes this process in response to exercise 
to maintain a balance between energy need and energy supply (13, 14). Furthermore, two recent 
microarray studies have implicated decreased PGC-1α expression and reduction in the 
expression of OXPHOS genes encoded by PGC-1α in the pathogenesis of type 2 diabetes 
mellitus (15, 16). Therefore, we hypothesized that increased expression of PGC-1α would 
prevent against fat induced insulin resistance. Given the important role of PGC-1α in stimulating 
mitochondrial biogenesis and potentially affecting the balance between fatty acid 
delivery/synthesis versus fatty acid oxidation in muscle, we decided to examine the impact of 
  Choi et al. 
  
  
4
increased PGC-1α expression on in vivo muscle mitochondrial function and glucose and lipid 
metabolism in muscle specific PGC-1α transgenic mice fed a high fat diet. 
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Results  
Increased expression of PGC-1α in muscle elevated mitochondrial density and OXPHOS 
genes. 
MCK-PGC-1α transgenic (MPGC-1α TG) mice had an ~6 fold increase in gene expression of 
PGC-1α (Figure 1A) and 2.4 fold higher mitochondrial density in the extensor digitorum longus 
muscle (EDL, mainly type II fibers), assessed by electron microscopy, as compared with WT 
mice (Figure 1B). The expression of a number of OXPHOS and mitochondrial genes was 
significantly increased including subunits of NADH-ubiquinone oxidoreductase (Ndufs1 and 
Ndufv2), cytochrome c (Cycs), cytochrome c oxidase (Cox5b) and ATP synthase (APT5o), 
which have been shown to be directly regulated by PGC-1α (Figure 1C). However, there was no 
difference in mitochondrial density in soleus muscle (type I fiber muscle, data not shown), which 
indicates that increased expression of PGC-1α was predominant in type II fibers of MPGC-1α 
TG mice due to preferential expression of the MCK promoter in this fiber-type.  
 
Increased expression of PGC-1α in muscle did not change fat mass or energy expenditure.  
Total body weight, fat mass and lean body mass were similar between MPGC-1α TG and WT 
littermate mice fed a regular diet. High fat feeding for 3 weeks increased fat mass in MPGC-1α 
TG to the same extent as in WT littermates (Table 1). To assess energy balance, mice were 
housed in metabolic cages for 4 days (2 day acclimation followed by 2 day study). Consistent 
with the effects on body weight change, no differences in food intake, activity and total energy 
expenditure were observed between MPGC-1α TG and WT mice fed either regular chow or high 
fat diet (Table 1). The respiratory quotient (RQ), which represents substrate preference as fuel, 
indicated that whole body fat oxidation was unaffected in MPGC-1α TG fed a regular-chow 
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[carbohydrate rich (12% fat)] diet. Switching WT mice to a high-fat diet (55% fat) significantly 
increased fat oxidation (reduced RQ) in the fed state, whereas altering the diet failed to increase 
fat oxidation any further in MPGC-1α TG mice. These data demonstrate that increased PGC-1α 
gene expression and mitochondrial density in skeletal muscle does not alter whole body energy 
expenditure, body weight or fat mass.  
 
Insulin sensitivity was paradoxically decreased in MPGC-1α TG mice fed a high-fat diet. 
Fasting plasma glucose and insulin concentrations were similar between the two groups, fed 
either the regular or high-fat diet (Table 2). Plasma lipid profiles, including plasma fatty acids, 
triglycerides and cholesterol were similar under fasting and insulin-stimulated conditions in both 
groups fed either regular or high-fat diet (Table 2). No difference in insulin sensitivity, assessed 
by the hyperinsulinemic-euglycemic clamp, was observed in the two groups of mice when fed a 
regular diet (data not shown). In contrast, MPGC-1α TG mice were insulin resistant compared to 
WT control mice when fed a high-fat fed diet, reflected by a 60% reduction in the glucose 
infusion rate required to maintain euglycemia during the clamp (Figure 2A). The whole body 
insulin resistance could be mostly attributed to a 25% reduction in insulin-stimulated whole body 
glucose uptake and a 56% reduction in whole body glycogen synthesis (Figure 2C).  There were 
no differences in basal or insulin mediated suppression of hepatic glucose production between 
the groups (Figure 2B). Consistent with the peripheral insulin resistance observed during the 
clamp, 2-deoxy-glucose uptake was decreased by 60% in MPGC-1α TG mice, compared with 
WT mice (Figure 2D). These changes were associated with a reduction in insulin-stimulated 
IRS1 tyrosine phosphorylation and Akt2 activity (Figure 2E, F).  
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Mechanism for increased insulin resistance in skeletal muscle in PGC-1α TG mice. 
Consistent with our hypothesis of lipid metabolites inducing insulin resistance (6, 9, 10, 17-20),   
muscle triglyceride, lysophosphatidic acid and long chain acyl CoAs were markedly increased in 
MPGC-1α TG mice fed a high fat diet, compared with WT mice (Figure 3A, C, D). The 
membrane/cytosol ratio of skeletal muscle diacylglycerol, a known activator of PKCs, was 
increased by ~50% in the MPGC-1α TG mice compared to WT mice (Figure 3B) and was 
associated with a 40% increase in PKCθ activity, as reflected by an increase in PKCθ 
translocation from cytosol to membrane (Figure 3E). 
A recent study suggested that PGC-1α induces insulin resistance in liver through 
peroxisome proliferator–activated receptor (PPAR)-α dependent induction of mammalian tribbles 
homolog (TRB-3), which has been suggested to be a direct negative regulator of AKT activity in 
some (21, 22), but not all studies (23, 24). Since overexpression of PGC-1α was also found to 
significantly increase TRB-3 expression in skeletal muscle (25) we examined TRB-3 gene 
expression in muscle of MPGC-1α TG mice. TRB-3 mRNA and protein levels were 
approximately twofold increased in MPGC-1α TG mice, compared with WT mice (Figure 4A, 
B).  
 
Muscle oxidative function in vivo and ex vivo.  
Net intracellular lipid accumulation in skeletal muscle can occur as a result of increased fatty 
acid delivery/synthesis and/or reduced fatty acid oxidation. To estimate mitochondrial function 
in vivo we used 31P saturation-transfer MRS to assess the unidirectional rate of muscle ATP 
synthesis (VATP) (33, 35). Skeletal muscle VATP was increased by 50-60% in the hindlimb of 
MPGC-1α TG mice fed either regular or high-fat diet compared to the WT mice (Figures 5A, B). 
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In addition, the ratio of inorganic phosphate to phosphocreatine was increased by 53% in 
MPGC-1α TG mice fed HFD compared to WT mice (0.236 ± 0.01 vs. 0.154 ± 0.01, P< 0.001), 
which may reflect a higher ratio of type I fibers (mostly oxidative) to type II fibers (mostly 
glycolytic) (27). Rates of fat oxidation measured ex vivo in isolated muscle strips, were increased 
by 30% in the EDL (predominantly type IIb muscle fibers) of MPGC-1α TG mice compared to 
WT mice, but were unaltered in soleus muscle (mainly type I muscle fibers) (Figures 5 C, D).  
 
Gene expression involved in fatty acid oxidation and uptake. 
Consistent with effects on muscle oxidative function, the expression of several 
oxidative/thermogenic genes (CPT1, CPT2, VLCAD, LCAD, MCAD and UCP2) and of CPT1 
protein were increased in the tibialis anterior muscle (predominantly type II muscle fibers) of 
MPGC-1α TG mice with respect to WT mice (Figure 5E, F). In addition, gene and protein 
expression of ACC2 was increased and the phospho-ACC2 level was also increased in MPGC-
1α TG mice compared to WT mice (Figure 5E, F). However, there was no difference in AMPK-
α2 activity in the EDL muscle, between the two groups [WT (n=6) vs.TG mice (n=6): 0.63 ± 
0.08 vs. 0.58 ± 0.18 pmol/min/mg, NS]. There was a marked increase in the expression of genes 
of fatty acid transport (CD36) and fatty acid reesterification (mtGPAT and DGAT1) in skeletal 
muscle of the MPGC-1α TG mice compared to the WT mice (Figure 6).  
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Discussion 
Given the important role that muscle mitochondria play in whole body glucose and fat 
metabolism we sought to examine the impact of increased mitochondrial content on oxidative 
metabolism and fat-induced insulin resistance in transgenic mice with increased expression of 
PGC-1α in skeletal muscle. We found that the increased mitochondrial content in these 
transgenic mice was accompanied by increased oxidative metabolism measured both in vivo and 
ex vivo, however this did not prevent diet-induced obesity. Furthermore, MPGC-1α TG mice 
were more prone to fat-induced muscle insulin resistance, which could be attributed to reduced 
insulin-stimulated glucose uptake in skeletal muscle. 
These results are contrary to previous studies that found increased glucose uptake in 
both C2C12 and L6 muscle cells that overexpressed PGC-1α (28) and ex vivo muscle with 
electrotransfection of PGC-1α (29). It is possible that the differences in these results may be due 
to the relatively higher expression of PGC-1α in the transgenic mice compared to the in vitro 
studies. However, it should be noted that the increased expression of PGC-1α in muscles 
composed of type II fibers was approximately 6 fold, which is well within the 10-13 fold 
increase observed following exercise training, and similar to that found in type I muscle fibers 
(30). Moreover, in contrast to the current in vivo studies, insulin sensitivity under conditions of 
increased fatty acid exposure was not tested in these in vitro cultured cell and ex vivo muscle 
studies (28, 29).  
To understand the mechanism for the reduced insulin-stimulated glucose uptake in 
skeletal muscle in the MPGC-1α TG mice we examined the insulin signaling pathway and found 
that both insulin-stimulated IRS-1 tyrosine phosphorylation and insulin-stimulated AKT2 
activity were significantly reduced in skeletal muscle. In addition, we found that the expression 
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of TRB-3, a mammalian homolog of Drosophila tribble, which has recently been suggested by 
some (21, 22) but not all studies (23, 24) to be a direct negative regulator of AKT activity, was 
increased by approximately twofold in skeletal muscle of the PGC-1α TG mice, consistent with 
previous observations (25). However, given the controversy regarding the role of TRB-3 in 
causing insulin resistance, further studies will be necessary to determine if increased TRB-
expression contributes to the observed insulin resistance in MPGC-1α TG mice. Furthermore, 
since TRB-3 has been implicated to cause insulin resistance at the level of AKT2 it cannot 
explain the reduced insulin-stimulated IRS-1 tyrosine phosphorylation. Previous studies have 
implicated that increases in intracellular diacylglycerol, due to an imbalance between fatty acid 
delivery/synthesis and fatty acid oxidation, results in activation of PKCθ which reduces insulin 
signaling at the level of the insulin receptor and IRS-1 tyrosine phosphorylation in muscle (6, 17). 
Consistent with this hypothesis, we observed increases in the membrane/cytosol ratio of 
diacylglycerol, associated with increased activation of PKCθ in the MPGC-1α TG mice. 
This was an unexpected result given the twofold increase in mitochondrial content. To 
determine whether the mitochondria were dysfunctional we examined a biomarker of in vivo 
mitochondrial function in the MPGC-1α TG mice with 31P saturation-transfer MRS (26). Using 
this approach we found that mitochondrial ATP synthesis per gram muscle was increased by 
60% in the MPGC-1α TG mice. This was somewhat less than the 2.4 fold increase in 
mitochondrial density, suggesting partial downregulation of activity per unit of mitochondrial 
mass in the MPGC-1α TG mice. However, the mechanism responsible for this effect remains to 
be determined. Despite increased muscle ATP production in vivo, and enhanced fat oxidation ex 
vivo, in MPGC-1α TG mice, no effects on whole body energy expenditure could be detected. 
Potentially, these mice could have enhanced mitochondrial coupling of oxidative 
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phosphorylation (an elevated P:O ratio). We have estimated the efficiency of mitochondrial 
energy production, in vivo, in a variety of human and animal models using MRS biomarkers of 
mitochondrial metabolism and have found that the P:O ratio is unaffected (26, 31) unless 
mitochondrial coupling is deliberately targeted (e.g. by T3 and 2,4 dinitrophenol treatment) or by 
modulating uncoupling protein expression (32-34). More recently, we have observed that 
endurance trained human muscle, likely to have an increased mitochondrial content, is actually 
less well coupled under resting conditions (35). Therefore, we believe that modulation of the P:O 
ratio is unlikely to cause the effects observed in these mice. A more likely explanation is that the 
measurement of whole body energy expenditure is not sensitive enough to detect an increase in 
muscle ATP production.  
Given the significant increase in intramuscular triglyceride and fat metabolites in the 
MPGC-1α TG mice, despite a concomitant increase in mitochondrial function and fatty acid 
oxidation, we investigated whether this could be attributed to increased fatty acid delivery and/or 
fat synthesis in the skeletal muscle of these mice. Consistent with this hypothesis we found that 
gene expression for CD36, a key fatty acid transporter, and mtGPAT and DGAT1, two key rate 
controlling enzymes for triglyceride reesterification, were markedly increased in the muscle of 
the MPGC-1α TG mice. It has been demonstrated that PGC-1α coactivates PPARs and the 
promoter of CD36 has a PPAR response element sequence (36), therefore increased expression 
of PGC-1α could result in enhanced CD36 expression and increased uptake of fatty acids. 
However, the mechanism by which increased PGC-1α expression elevates the gene expression of 
mtGPAT and DGAT1 is less clear. PGC-1α, in contrast to PGC-1β, is not known to regulate 
SREBP1c activity (37), although it is possible that interactions via LXR could affect these genes 
(37, 38).  
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Taken together these data are consistent with the hypothesis that under normal 
physiologic conditions of exercise, PGC-1α induces a coordinated program of increased energy 
delivery and increased mitochondrial biogenesis and fatty acid oxidation to meet the increased 
energy demands of working skeletal muscle. In contrast, this same coordinated program, in the 
non exercising MPGC-1α TG mice, results in a mismatch between increased fatty acid uptake 
and that of mitochondrial fat oxidation resulting in a net increase intramyocellular fat and 
diacylglycerol content and insulin resistance. Recently Koves et al. have proposed that fat-
induced insulin resistance in muscle might also arise from increased fatty acid transport into 
mitochondria resulting in incomplete β-oxidation (39). Further studies will be necessary to 
determine if this mechanism is also contributing to skeletal muscle insulin resistance in this 
mouse model. 
In summary, we have shown that increased muscle expression of PGC-1α paradoxically 
exacerbated fat-induced insulin resistance in skeletal muscle despite an increase in mitochondrial 
density and mitochondrial activity. This insulin resistance could be attributed to net increases in 
the membrane/cytosol diacylglycerol content, due to relative increases in fatty acid uptake and 
reesterification exceeding mitochondrial fatty acid oxidation. The increase in membrane/cytosol 
diacylglycerol content in turn leads to activation of PKCθ and decreased insulin signalling at the 
level of IRS-1 tyrosine phosphorylation and results in insulin resistance in skeletal muscle.  
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Materials and Methods 
Animals. MPGC-1α TG mice were generated as previously described (40). PGC-1α 
complementary DNA was placed downstream of a 6.5-kilobase (kb) MCK promoter sequence. 
MPGC-1α TG mice were generated by standard DNA microinjection and identified by PCR-
based genotyping. Male MPGC-1α TG mice and littermates (12-14 weeks of age) were studied 
under controlled temperature (22±2oC) and lighting (12-h light; 0700-1700 h, 12-h dark; 1700-
0700 h). To examine diet-induced changes in glucose and fat metabolism, male MPGC-1α TG 
and WT mice were fed with high-fat diet (55% fat by calories; Harlan Teklad, Madison, WI) ad 
libitum for 3 weeks. All mice were maintained in accordance with the institutional Animal Use 
and Care Committee of Yale University School of Medicine.    
Basal metabolic parameters. Fat and lean body masses were assessed by a 1H minispec system  
(Bruker BioSpin, Billerica, MA) before and after 3 week’s high fat feeding. Activity, food 
consumption, and energy expenditure were evaluated before and after 3 weeks of high fat 
feeding (CLAMS: Columbus instruments, Columbus, OH, USA) as previously described (10).  
Hyperinsulinemic-euglycemic clamp study. After an overnight fast, hyperinsulinemic-
euglycemic clamp was conducted for 120 min with a primed/continuous infusion of human 
insulin (126 pmol/kg prime, 18 pmol/kg/min infusion) (Novo Nordisk, Princeton, NJ) as 
previously described (10). During the clamp, plasma glucose was maintained at basal 
concentrations (~6.7 mM). Rates of basal and insulin-stimulated whole-body glucose fluxes and 
tissue glucose uptake were determined as previously described (10).  
Biochemical Analysis. Plasma glucose and insulin were determined by a glucose oxidase 
method (Beckman glucose analyzer II, Beckman, Fullerton, CA) and radioimmunoassay (RIA kit 
from Linco Research, St. Louis, MO, U.S.A.). Plasma FFA was determined using an acyl-CoA 
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oxidase based colorimetric kit (Wako Pure Chemical Industries, Osaka, Japan). Plasma resistin, 
leptin, TNFα and IL-6 were measured by multiplexed biomarker immunoassays (Lincoplex) 
from Linco Research (St. Charles, MO, U.S.A.).  
Insulin signaling and PKCθ. IRS1 tyrosine phosphorylation and Akt2 activity were assessed in 
protein extracts from muscle harvested after short-term insulin stimulation as previously 
described (10). Primary antibodies used for experiments were rabbit polyclonal IgG: Antibodies 
for IRS1 tyrosine phosphorylation and Akt2 were obtained from Upstate (Charlottesville, 
Virginia, USA). PKCθ membrane translocation assay was conducted as previously described 
(10). Membrane translocation of PKCθ was expressed as the ratio of membrane bands over 
cytosol bands (arbitrary units).  
Total RNA preparation, real-time quantitative RT-PCR analysis and immunoblotting 
analysis. Total RNA was isolated from tibialis anterior muscle of the mice fed regular diet using 
total RNA isolation reagent (BL-10500, Biotecx Laboratories Inc.). Quantitative RT-PCR was 
performed using custom-made RT-PCR enzymes and reagents kit (Invitrogen Life Technology 
Inc.) and ABI Prism 7700 Sequence Detector (PE Applied Biosciences). For Western protein 
analysis, forty micrograms of cell lysates were separated on 4-12% SDS-PAGE and 
immunoblotted with TRB3 (provided by Marc Montminy), CPT1 (Santa Cruz biotechnology), 
ACC2 (Santa Cruz biotechnology) or anti-p-ACC 2 (Ser219/221, Santa Cruz biotechnology) 
antibodies.  
AMPK activity assays: The EDL muscle was quickly freeze-clamped in situ and kept in liquid 
nitrogen until analyzed. AMPK activity was assessed previously described (41). Muscles were 
ground and mixed with 1 ml of lysis buffer. Homogenates were spun at 20,800 × g for 10 min at 
4°C, and protein concentrations were determined. AMPK-α2 was immunoprecipitated overnight 
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from cell lysates containing 1 mg of protein using 1 μl of AMPK-α2 antibody (Santa Cruz 
Biotechnology). Skeletal muscle AMPK-α2 activity was determined by following the 
incorporation of [32P]ATP into a synthetic peptide containing the AMARA sequence on the 
following day. 
 
Transmission electron microscopy analysis. Mitochondrial density was assessed by a Tecnai 
12 BiolTWIN electron microscopy (FEI Co.) in soleus and EDL muscle as previously described 
(18). For each set of 5 pictures from 3 random sections of individual muscle, average volume 
density was calculated and the mean of 3 values used to estimate the volume density for each 
muscle.  
Tissue lipid measurement. Intracellular fatty acid metabolites, such as lysophosphatidic acid 
and long-chain fatty acyl-CoAs  were measured by using an API 4000 tandem mass spectrometer 
(Applied Biosystems) in conjunction with two Perkin Elmer 200 Series micro pumps and a 200 
Series autosampler (Perkin Elmer) (8). To determine the level of diacylglycerol in cytosol and 
membrane, diacylglycerol extraction and analysis in both cytosolic and membrane samples was 
performed as previously described (8, 19).  Tissue triglyceride was extracted using the method of 
Bligh and Dyer (42) and measured using a DCL Triglyceride Reagent (Diagnostic Chemicals 
Ltd.).  
Skeletal muscle fatty acid oxidation rate. Skeletal muscle (about 10~15 mg of soleus and EDL 
muscles) was quickly removed from mice and muscle fatty acid oxidation was assessed with 
trapping 14CO2 after incubation with albumin bound 2uCi of [1-14C] oleic acid (43). 
Unidirectional rate of muscle ATP synthesis by in vivo 31P-MRS. The unidirectional rate of 
muscle ATP synthesis (VATP) was assessed by 31P saturation-transfer MRS using a 9.4 T 
superconducting magnet (Magnex Scientific, UK) interfaced to a Bruker Biospec console. After 
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an overnight fast, the mouse was sedated using ~1% isoflurane and the left hindlimb was 
positioned under a 15mm diameter 31P surface coil. Non-localized 31P saturation-transfer spectra 
were acquired with saturation of the γ-ATP resonance or at a downfield frequency equidistant 
from the Pi resonance (control saturation) using the following parameters: 1ms AHP excitation 
pulse (centered between Pi and γ-ATP) 10s frequency-selective saturation pulse, sweep width = 
8 kHz, 1024 complex points, effective TR = 10s, 64 averages. Fully-relaxed 31P spectra (TR = 25 
sec, 32 averages) were also obtained to determine metabolite concentrations. The T1 of Pi under 
γ-ATP saturation (T1’) was measured using an 8-point inversion-recovery sequence (2ms AFP 
inversion pulse) with γ-ATP-saturation prior to and during the inversion delay. All MR data was 
processed using XWINNMR (version 6.5; Bruker Biospin, Germany); prior to Fourier 
transformation 31P FIDs were zero-filled to 32k points and multiplied by a mixed Lorentzian / 
Gaussian function (lb -20/ gb 0.04). 31P spectra were baseline corrected by fitting to a 5th order 
polynomial. The unidirectional rate of Pi → ATP flux was determined as previously described  
(33, 35). 
 
Statistics 
All results are expressed as means ± SEM of ‘n’ observations. Statistical differences between the 
means were assessed by a 2-tailed Student’s t-test, *P < 0.05.  
  Choi et al. 
  
  
17
Acknowledgements 
We thank Mario Kahn and Xiaoxian Ma for expert technical assistance with the studies. This 
work was supported by grants from the United States Public Health Services, R01 DK-40936, 
U24 DK-76169 and P30 DK-45735 (to G.I.S.). G. I. Shulman is an investigator of The Howard 
Hughes Medical Institute and the recipient of a Distinguished Clinical Investigator Award from 
the American Diabetes Association.  
 
  Choi et al. 
  
  
18
References 
 
1. Zimmet P, Alberti KG, & Shaw J (2001) Global and societal implications of the diabetes 
epidemic. Nature 414(6865):782-787. 
2. Lillioja S, et al. (1993) Insulin resistance and insulin secretory dysfunction as precursors 
of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J 
Med 329(27):1988-1992. 
3. DeFronzo RA, Bonadonna RC, & Ferrannini E (1992) Pathogenesis of NIDDM. A 
balanced overview. Diabetes Care 15(3):318-368. 
4. Boden G & Shulman GI (2002) Free fatty acids in obesity and type 2 diabetes: defining 
their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin 
Invest 32 Suppl 3:14-23. 
5. Kim JK, et al. (2001) Tissue-specific overexpression of lipoprotein lipase causes tissue-
specific insulin resistance. Proc Natl Acad Sci U S A 98(13):7522-7527. 
6. Shulman GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106(2):171-
176. 
7. Kim JK, et al. (2004) Inactivation of fatty acid transport protein 1 prevents fat-induced 
insulin resistance in skeletal muscle. J Clin Invest 113(5):756-763. 
8. Neschen S, et al. (2005) Prevention of hepatic steatosis and hepatic insulin resistance in 
mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell 
Metab 2(1):55-65. 
9. Choi CS, et al. (2007) Overexpression of uncoupling protein 3 in skeletal muscle protects 
against fat-induced insulin resistance. J Clin Invest 117(7):1995-2003. 
10. Choi CS, et al. (2007) Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout 
mice increases total energy expenditure, reduces fat mass, and improves insulin 
sensitivity. Proc Natl Acad Sci U S A 104(42):16480-16485. 
11. Zhang D, et al. (2007) Mitochondrial dysfunction due to long-chain Acyl-CoA 
dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. Proc 
Natl Acad Sci U S A 104(43):17075-17080. 
12. Neschen S, et al. (2007) n-3 Fatty acids preserve insulin sensitivity in vivo in a 
peroxisome proliferator-activated receptor-alpha-dependent manner. Diabetes 
56(4):1034-1041. 
13. Puigserver P, et al. (1999) Activation of PPARgamma coactivator-1 through transcription 
factor docking. Science 286(5443):1368-1371. 
14. Wu Z, et al. (1999) Mechanisms controlling mitochondrial biogenesis and respiration 
through the thermogenic coactivator PGC-1. Cell 98(1):115-124. 
15. Mootha VK, et al. (2003) PGC-1alpha-responsive genes involved in oxidative 
phosphorylation are coordinately downregulated in human diabetes. Nat Genet 
34(3):267-273. 
16. Patti ME, et al. (2003) Coordinated reduction of genes of oxidative metabolism in 
humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl 
Acad Sci U S A 100(14):8466-8471. 
17. Griffin ME, et al. (1999) Free fatty acid-induced insulin resistance is associated with 
activation of protein kinase C theta and alterations in the insulin signaling cascade. 
Diabetes 48(6):1270-1274. 
  Choi et al. 
  
  
19
18. Morino K, et al. (2005) Reduced mitochondrial density and increased IRS-1 serine 
phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin 
Invest 115(12):3587-3593. 
19. Yu C, et al. (2002) Mechanism by which fatty acids inhibit insulin activation of insulin 
receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. 
J Biol Chem 277(52):50230-50236. 
20. Kim JK, et al. (2004) PKC-theta knockout mice are protected from fat-induced insulin 
resistance. J Clin Invest 114(6):823-827. 
21. Du K, Herzig S, Kulkarni RN, & Montminy M (2003) TRB3: a tribbles homolog that 
inhibits Akt/PKB activation by insulin in liver. Science 300(5625):1574-1577. 
22. Koo SH, et al. (2004) PGC-1 promotes insulin resistance in liver through PPAR-alpha-
dependent induction of TRB-3. Nat Med 10(5):530-534. 
23. Iynedjian PB (2005) Lack of evidence for a role of TRB3/NIPK as an inhibitor of PKB-
mediated insulin signalling in primary hepatocytes. Biochem J 386(Pt 1):113-118. 
24. Okamoto H, et al. (2007) Genetic deletion of Trb3, the mammalian Drosophila tribbles 
homolog, displays normal hepatic insulin signaling and glucose homeostasis. Diabetes 
56(5):1350-1356. 
25. Mortensen OH, Frandsen L, Schjerling P, Nishimura E, & Grunnet N (2006) PGC-1alpha 
and PGC-1beta have both similar and distinct effects on myofiber switching toward an 
oxidative phenotype. Am J Physiol Endocrinol Metab 291(4):E807-816. 
26. Petersen KF, et al. (2003) Mitochondrial dysfunction in the elderly: possible role in 
insulin resistance. Science 300(5622):1140-1142. 
27. Kushmerick MJ, Moerland TS, & Wiseman RW (1992) Mammalian skeletal muscle 
fibers distinguished by contents of phosphocreatine, ATP, and Pi. Proc Natl Acad Sci U S 
A 89(16):7521-7525. 
28. Michael LF, et al. (2001) Restoration of insulin-sensitive glucose transporter (GLUT4) 
gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad 
Sci U S A 98(7):3820-3825. 
29. Benton CR, et al. (2007) Modest PGC-1alpha overexpression in muscle in vivo is 
sufficient to increase insulin sensitivity and palmitate oxidation in SS, not IMF, 
mitochondria. J Biol Chem. 
30. Miura S, Kai Y, Ono M, & Ezaki O (2003) Overexpression of peroxisome proliferator-
activated receptor gamma coactivator-1alpha down-regulates GLUT4 mRNA in skeletal 
muscles. J Biol Chem 278(33):31385-31390. 
31. Befroy DE, et al. (2007) Impaired mitochondrial substrate oxidation in muscle of insulin-
resistant offspring of type 2 diabetic patients. Diabetes 56(5):1376-1381. 
32. Lebon V, et al. (2001) Effect of triiodothyronine on mitochondrial energy coupling in 
human skeletal muscle. J Clin Invest 108(5):733-737. 
33. Jucker BM, et al. (2000) Assessment of mitochondrial energy coupling in vivo by 
13C/31P NMR. Proc Natl Acad Sci U S A 97(12):6880-6884. 
34. Cline GW, et al. (2001) In vivo effects of uncoupling protein-3 gene disruption on 
mitochondrial energy metabolism. J Biol Chem 276(23):20240-20244. 
35. Befroy D, et al. (2008 in press) Increased Substrate Oxidation and Mitochondrial 
Uncoupling in Skeletal Muscle of Endurance Trained Individuals. Proc Natl Acad Sci U 
S A. 
  Choi et al. 
  
  
20
36. Teboul L, et al. (2001) Structural and functional characterization of the mouse fatty acid 
translocase promoter: activation during adipose differentiation. Biochem J 360(Pt 2):305-
312. 
37. Lin J, et al. (2005) Hyperlipidemic effects of dietary saturated fats mediated through 
PGC-1beta coactivation of SREBP. Cell 120(2):261-273. 
38. Oberkofler H, Schraml E, Krempler F, & Patsch W (2003) Potentiation of liver X 
receptor transcriptional activity by peroxisome-proliferator-activated receptor gamma co-
activator 1 alpha. Biochem J 371(Pt 1):89-96. 
39. Koves TR, et al. (2008) Mitochondrial overload and incomplete fatty acid oxidation 
contribute to skeletal muscle insulin resistance. Cell Metab 7(1):45-56. 
40. Lin J, et al. (2002) Transcriptional co-activator PGC-1 alpha drives the formation of 
slow-twitch muscle fibres. Nature 418(6899):797-801. 
41. Reznick RM, et al. (2007) Aging-associated reductions in AMP-activated protein kinase 
activity and mitochondrial biogenesis. Cell Metab 5(2):151-156. 
42. Bligh EG & Dyer WJ (1959) A rapid method of total lipid extraction and purification. 
Can J Biochem Physiol 37(8):911-917. 
43. Cha SH, Hu Z, Chohnan S, & Lane MD (2005) Inhibition of hypothalamic fatty acid 
synthase triggers rapid activation of fatty acid oxidation in skeletal muscle. Proc Natl 
Acad Sci U S A 102(41):14557-14562. 
 
  Choi et al. 
  
  
21
 
 
Table 1 
Basal metabolic parameters of energy balance 
Group Regular diet High fat diet 
 WT (n=8) 
MPGC-1α TG 
(n=8) 
WT 
(n=8) 
MPGC-1α TG 
 (n=8) 
Body weight (g) 28.6 ± 0.4 28.2 ± 0.8  32.4 ± 0.7 32.3 ± 0.8  
Fat mass (g) 1.91 ± 0.2 2.1 ± 0.3 5.64 ± 0.6 5.9 ± 0.5  
Lean body mass (g) 22.2 ± 0.4 21.7 ± 0.7   22.3 ± 0.2 22.3 ± 0.4   
Total Energy Expenditure 
 (Kcal /h/Kg body mass) 16.0 ± 0.8 15.1 ± 0.8
  16.5 ± 0.3 16.1 ± 0.9 
Food intake  
(Kcal /h/Kg body mass) 18.3 ± 1.5 15.5 ± 1.6 19.7 ± 2.3 18.1 ± 2.6 
Activity (count/h) 103.5 ± 26.3 111.0 ± 21.5 110.4 ± 19.7 81.1 ± 26.0 
Respiratory quotient 0.929 ± 0.012 0.880 ± 0.023 0.840 ± 0.010 0.820 ± 0.010 
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Table 2 
Plasma metabolite, hormone and cytokine data from high fat fed wild type and PGC-1α TG mice 
 Regular diet High fat diet 
Group Fast  Clamp  Fast  Clamp  
 WT 
(n=9) 
MPGC1α TG 
(n=9) 
WT 
(n=9) 
MPGC1α TG 
(n=9) 
WT 
(n=7~9) 
MPGC1α TG 
(n=7~9) 
WT 
(n=9) 
MPGC1α TG 
(n=6) 
Glucose (mg/dl) 150 ± 11 142 ± 9  118 ± 3 114 ± 4 160 ± 7 164 ± 10  123 ± 3 119 ± 5 
Insulin (μU/ml) 14.6 ± 1.7 13.4 ± 1.6 61.4 ± 5.8 63.1 ± 5.4 17.7 ± 1.6 20.3 ± 1.2  60.9 ± 5.2 73.3 ± 5.2 
Fatty Acids (mEq/l) 0.98 ± 0.11 1.27 ± 0.13 0.58 ± 0.06 0.48 ± 0.09  0.98 ± 0.09 1.00 ± 0.04 0.90 ± 0.07 0.83 ± 0.06  
Triglycerides 
(mg/dl) 
    
69.5 ± 9.1 83.2 ± 7.9 nd nd 
Cholesterol (mg/dl) 
    
91.1 ± 7.7 88.9  ± 2.5 nd nd 
β-hydroxbutarate 
(mM) 
    
1.47 ± 0.25 0.9 ± 0.10† nd nd 
nd: not determined. 
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Figure Legends  
 
Figure 1. Increased expression of PGC-1α in muscle elevated mitochondrial density and 
OXPHOS genes. Total RNA was isolated from tibialis anterior muscle of the mice fed a regular 
diet (n = 5), PGC-1α (A) and OXPHOS gene (C) expression was assessed by realtime RT-PCR. 
Mitochondrial density was counted in the extensor digitorum longus muscle (n = 5), the arrow 
indicates a mitochondrion (B). APT5o, ATP synthase; Ndufs, NADH-ubiquinone 
oxidoreductase; Cycs, cytochrome c; Cox5b, cytochrome c oxidase;  
 
Figure 2. Increased expression of PGC-1α in skeletal muscle paradoxically decreased 
peripheral insulin sensitivity in high-fat fed mice. Peripheral and hepatic insulin sensitivity 
was assessed by a hyperinsulinemic-euglycemic clamps (A-D). (A) glucose infusion rates; (B) 
hepatic glucose production; (C) whole body glucose uptake, glycolysis and glycogen synthesis; 
(D) Skeletal muscle (gastrocnemius) glucose uptake. Consistent with decreased muscle insulin 
sensitivity, IRS1 tyrosine phosphorylation and AKT2 activity in skeletal muscle (gastrocnemius) 
were decreased in MPGC-1α TG compared to wild type mice (E, F). IRS1 tyrosine 
phosphorylation and Akt2 activity were assessed 14 minutes after an intraperitoneal insulin 
injection of 1 u/kg body weight. n = 6 – 8 per group. 
  
Figure 3. Fat metabolites and membrane translocation of PKCθ were increased in skeletal 
muscle of MPGC-1α TG mice. Triglyceride (A), lysophosphatidic acid (C) and long chain acyl 
CoA (D) levels were significantly increased in muscle (gastrocnemius) in MPGC-1α TG mice. 
Membrane/cytosol ratio of diacylglycerol (B) and PKCθ (E) were significantly higher in muscle 
(gastrocnemius) of MPGC-1α TG mice compared with WT mice. n = 8 per group. 
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Figure 4. Increased expression of PGC-1α in muscle also elevated TRB-3 gene (n = 8) and 
protein expression (n = 4) in skeletal muscle. Total RNA was isolated from tibialis anterior 
muscle, TRB3 gene expression (A) was assessed by realtime RT-PCR, protein expression was 
confirmed by immunoblot (B).  
 
Figure 5.  In vivo rates of ATP production and ex vivo fat oxidation were increased in the 
muscle of increased PGC-1α expression. Saturation-transfer measurements of ATP synthesis 
rates (VATP) by 31P-MRS in hind limb of mice (n = 6) on regular chow (A) and high fat diet (B). 
Ex vivo skeletal muscle fat oxidation rate in soleus muscle (C) and EDL muscle from mice (n = 
6) fed a regular chow (D). The expression of oxidative/thermogenic genes in tibialis anterior 
muscle from mice (n = 5 - 6) fed regular chow assessed by realtime RT-PCR (E). Immunoblot 
analysis (n = 4) from selected genes for CPT1, ACC2 and phospho-ACC2 (Ser219/221) (F). 
PPARα, peroxisome proliferator activated receptor α; ACC2, acetyl coenzyme A carboxylase 2; 
CPT, carnitine palmitoyl transferase; VLCAD, very long-chain acyl-CoA dehydrogenase; 
LCAD,  long-chain acyl-CoA dehydrogenase; MCAD, medium chain acyl-CoA dehydrogenase; 
UCP2, uncoupling protein 2.  
 
Figure 6. The expression of the genes involved in fatty acid uptake and reesterification was 
increased in tibialis anterior muscle of MPGC-1α TG mice fed a regular chow (n = 5 - 6).  
LPL, lipoprotein lipase ; mtGPAT, mitochondrial acyl CoA: glycerol-sn-3-phosphate 
acyltransferase ; DGAT1, acyl coenzyme A (CoA): diacylglycerol acyltransferase1 ;   SREBP1c, 
sterol-regulatory element binding protein 1c; LXRα, liver x receptor α;LXRβ, liver x receptor β  
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